| Trial ID: | L7269 |
| Source ID: | NCT03367377
|
| Associated Drug: |
Ly3209590
|
| Title: |
A Study of LY3209590 in Participants With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: LY3209590|DRUG: Insulin Glargine
|
| Outcome Measures: |
Primary: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration, A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module, Baseline through 17 weeks | Secondary: Pharmacokinetics (PK): Area Under the Drug Plasma Concentration Versus Time Curve from Time Zero to 168 hours (AUC[0-168]) of LY3209590, PK: AUC(0-168) of LY3209590, Week 6|Pharmacodynamics (PD): Average Glucose from 7-Point Glucose Profiles, PD: Average Glucose from 7-Point Glucose Profiles, Baseline, Day 4, Day 40, Day 43
|
| Sponsor/Collaborators: |
Sponsor: Eli Lilly and Company
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
70
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2018-01-03
|
| Completion Date: |
2018-10-03
|
| Results First Posted: |
|
| Last Update Posted: |
2018-12-11
|
| Locations: |
Miami Research Associates, South Miami, Florida, 33143, United States|High Point Clinical Trials Center, High Point, North Carolina, 27265, United States|LMC Endocrinology Centres Ltd., Toronto, Ontario, M4G 3E8, Canada
|
| URL: |
https://clinicaltrials.gov/show/NCT03367377
|
